---
title: Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac
  Transthyretin Amyloidosis
date: '2024-04-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38673530/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240427180604&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Introduction: Cardiac transthyretin amyloidosis (ATTR) is a progressive,
  fatal disease leading to heart failure due to accumulation of amyloid fibrils in
  the interstitial space and may occur as a hereditary (ATTRv) or wild-type (ATTRwt)
  form. Guidelines recommend the use of ACE inhibitors (ACEis) and beta-blockers (BBs)
  as heart failure therapy (HFT) in all patients with symptomatic heart failure and
  reduced ejection fraction, independent of the underlying etiology. However, the
  ...'
disable_comments: true
---
Introduction: Cardiac transthyretin amyloidosis (ATTR) is a progressive, fatal disease leading to heart failure due to accumulation of amyloid fibrils in the interstitial space and may occur as a hereditary (ATTRv) or wild-type (ATTRwt) form. Guidelines recommend the use of ACE inhibitors (ACEis) and beta-blockers (BBs) as heart failure therapy (HFT) in all patients with symptomatic heart failure and reduced ejection fraction, independent of the underlying etiology. However, the ...